Discover whether Moderna or BioNTech offers better long-term investment potential as both pivot from COVID-19 to innovative ...

A multi-institutional team led by University of Washington scientists have engineered a new vaccine platform combining mRNA ...

A team led by Neil King, a biochemistry professor at the University of Washington School of Medicine, is now exploring a new approach to COVID vaccines: using mRNA to let the body assemble its own ...

Professor from the Faculty of Medicine in Kragujevac Vladimir Jakovljevic said today that cooperation between Serbian and ...

Then, demand for its COVID-19 vaccine started to diminish. As hospitals resumed normal operations and anti-vaccine sentiment ...

RNA vaccines are quick and easy to make, while virus-like nanoparticles produce a stronger immune response. Now, the two ...

Groundbreaking Study Raises Serious Concerns About COVID mRNA Vaccine Safety** A recent peer-reviewed study has emerged that scrutinizes the safety and implications of COVID-19 ...

The global mRNA therapeutics CDMO market size is calculated at USD 5.15 billion in 2025 and is expected to reach around USD 13.63 billion by 2034, growing at a CAGR of 11.37% for the forecasted period ...

It’s that time of year when the leaves are turning golden, there’s a chill in the air and the threat of respiratory viruses ...

Moderna faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited ...

From Elon Musk and Satya Nadella to the co-founder of Moderna, it’s not just tycoons in Silicon Valley who have benefited ...